Tumor immunogenicity was important for synergy with immune checkpoint inhibition: anti-PD1 combined with Lrp10 deletion did not have a major effect in the B16F10 model where we had observed no primary effect on tumor growth or CD8 T-cell infiltration with Lrp10 deletion alone (Fig. EV5H). The gene discussed is LRP10; the disease is neoplasm.